Atlas Trials

Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment

Clinical trial NCT06662877 · NOT_YET_RECRUITING

Trial details

NCT number
NCT06662877
Sponsor
Sun Yat-sen University
Status
NOT_YET_RECRUITING
Phase
Phase 2, Phase 3
Study type
INTERVENTIONAL
Biliary Tract CancerSecond Line TreatmentChemotherapyTyrosine Kinase Inhibitor
Start date
2024-11-25
Primary completion
2029-09-01
Enrollment
206

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.